Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | TOP1 | P11387 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151598 | 1.00 | EPHX2 (0.36) | EPHX2PPARAFAAHCNR1CNR2 | |
| SCHEMBL29185782 | 1.00 | EPHX2 (0.36) | EPHX2PPARAFAAHCNR1CNR2 | |
| SCHEMBL30151581 | 1.00 | EPHX2 (0.36) | EPHX2PPARAFAAHCNR1CNR2 | |
| SCHEMBL30151585 | 0.84 | EPHX2 (0.38) | EPHX2PPARAFAAHCNR1CNR2 | |
| SCHEMBL30128945 | 0.84 | EPHX2 (0.38) | EPHX2PPARAFAAHCNR1CNR2 | |
| SCHEMBL29185757 | 0.84 | EPHX2 (0.38) | EPHX2PPARAFAAHCNR1CNR2 | |
| SCHEMBL29185849 | 0.83 | FAAH (0.41) | EPHX2PPARAFAAHCNR1CNR2 | |
| SCHEMBL30128674 | 0.83 | FAAH (0.41) | EPHX2PPARAFAAHCNR1CNR2 | |
| SCHEMBL30128893 | 0.82 | FAAH (0.43) | EPHX2PPARAFAAHCNR1CNR2 | |
| SCHEMBL30128676 | 0.82 | FAAH (0.43) | EPHX2PPARAFAAHCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294470-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2024-09-05 | — | — | US | disclosed |
| EP-4355728-A1 | FRAGRANCE COMPOUNDS | Givaudan SA (CH) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022263605-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294470-A1 | FRAGRANCE COMPOUNDS | FASN, FAAH2, FADS2 | EPHX2 364/4885PPARA 346/4885FAAH 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.